NUMEDII

numedii-logo

NuMedii is a biotechnology company that discovers and de-risks effective new drugs by translating life sciences big data into therapies. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii. It utilizes hundreds of millions of raw human, biological, pharmacological, and clinical data points. The company was founded in 2008 and headquartered in San Mateo, California.

#People #Financial #Website #More

NUMEDII

Social Links:

Industry:
Biotechnology Medical Therapeutics

Founded:
2008-01-01

Address:
Menlo Park, California, United States

Country:
United States

Website Url:
http://www.numedii.com

Total Employee:
11+

Status:
Active

Contact:
650-521-6363

Email Addresses:
busdev@numedii.com

Total Funding:
5.5 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Wordpress Plugins Google Apps For Business GoDaddy DNS



Current Advisors List

not_available_image

Sasha Elenski Investor @ NuMedii
Board_member
2013-01-01

Current Employees Featured

atul-butte_image

Atul Butte
Atul Butte Co-Founder & Scientific Advisor @ NuMedii
Co-Founder & Scientific Advisor
2011-01-01

linda-ara_image

Linda Ara
Linda Ara Chief Financial Officer @ NuMedii
Chief Financial Officer

gini-deshpande_image

Gini Deshpande
Gini Deshpande Founder and Chief Executive Officer @ NuMedii
Founder and Chief Executive Officer

mark-murcko_image

Mark Murcko
Mark Murcko Chair, SAB @ NuMedii
Chair, SAB
2014-03-01

Founder


atul-butte_image

Atul Butte

gini-deshpande_image

Gini Deshpande

joel-dudley_image

Joel Dudley

Investors List

seraph-group_image

Seraph Group

Seraph Group investment in Series A - NuMedii

tsvcap_image

TSVC

TSVC investment in Series A - NuMedii

lightspeed-venture-partners_image

Lightspeed Venture Partners

Lightspeed Venture Partners investment in Series A - NuMedii

stanfordstartx-fund_image

StartX (Stanford-StartX Fund)

StartX (Stanford-StartX Fund) investment in Series A - NuMedii

claremont-creek-ventures_image

Claremont Creek Ventures

Claremont Creek Ventures investment in Series A - NuMedii

claremont-creek-ventures_image

Claremont Creek Ventures

Claremont Creek Ventures investment in Series A - NuMedii

life-science-angels_image

Life Science Angels

Life Science Angels investment in Series A - NuMedii

lightspeed-venture-partners_image

Lightspeed Venture Partners

Lightspeed Venture Partners investment in Series A - NuMedii

Official Site Inspections

http://www.numedii.com Semrush global rank: 5.9 M Semrush visits lastest month: 1.4 K

  • Host name: 181.0.153.160.host.secureserver.net
  • IP address: 160.153.0.181
  • Location: Scottsdale United States
  • Latitude: 33.6013
  • Longitude: -111.8867
  • Metro Code: 753
  • Timezone: America/Phoenix
  • Postal: 85260

Loading ...

More informations about "NuMedii"

NuMedii – Disrupting Drug Discovery Using Big Data and Artificial ...

AI · BIG DATA · PRECISION THERAPEUTICS Disrupting Drug Discovery Using Big Data & Artificial IntelligenceSee details»

NuMedii - Crunchbase Company Profile & Funding

NuMedii is a biotechnology company that discovers and de-risks effective new drugs by translating life sciences big data into therapies. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at …See details»

Technology - NuMedii

NuMedii has been pioneering the use of Big Data, Artificial Intelligence (AI) and systems biology since 2010 to accelerate the discovery of precision therapies to address high unmet medical needs.See details»

Leadership - NuMedii

As CEO of NuMedii, Gini structured the company’s critical partnerships with some of the world’s largest pharmaceutical companies including Allergan, Astellas and Aptalis, and raised the …See details»

NuMedii - VentureRadar

NuMedii has active R&D collaborations with several global pharmaceutical and biotech companies and patient-centric organizations to create pipeline and new products in multiple therapeutic …See details»

NuMedii, Inc. Company Profile | San Martin, CA | Competitors ...

Find company research, competitor information, contact details & financial data for NuMedii, Inc. of San Martin, CA. Get the latest business insights from Dun & Bradstreet.See details»

NuMedii Company Profile 2024: Valuation, Funding

Operator of a biotechnology company intended to address unmet medical needs.See details»

NuMedii - LinkedIn

NuMedii | 893 followers on LinkedIn. NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success.See details»

NuMedii Company Profile - Office Locations, Competitors ... - Craft

The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of …See details»

NuMedii - Company info. interviews, news - biopharmatrend.com

Sep 12, 2018 Â· The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of …See details»

NuMedii - Contacts, Employees, Board Members, Advisors & Alumni

NuMedii is a biotechnology company that discovers and de-risks effective drugs by translating life sciences big data into therapies.See details»

NuMedii - Overview, News & Similar companies | ZoomInfo.com

Jul 9, 2020 Â· NuMedii contact info: Phone number: (650) 918-6363 Website: www.numedii.com What does NuMedii do? NuMedii discovers effective new targets, drugs and biomarkers via its …See details»

Partners – NuMedii

NuMedii has active R&D collaborations with several global pharmaceutical and biotech companies and patient-centric organizations to create pipeline and new products through the use of our …See details»

NuMedii Forms Advisory Board for AI Approach to Personalized …

Jan 11, 2018 Â· NuMedii is advancing the field of personalized medicine for idiopathic pulmonary fibrosis (IPF) by creating a new advisory board that includes some of the world’s leading …See details»

NuMedii Collaborating With Experts to Develop Precision Therapies...

Jul 13, 2018 Â· NuMedii will collaborate with researchers at Yale School of Medicine and Brigham and Women’s Hospital to develop precision therapies and biomarkers for idiopathic pulmonary …See details»

Careers - NuMedii

At NuMedii, we have created a dynamic, collaborative and inclusive environment. Our team members are skilled in data sciences, machine learning, drug discovery and drug …See details»

NuMedii, Inc. Announces Pharmaceutical Discovery Collaboration …

Jan 15, 2020 Â· NuMedii's proprietary and dynamic AIDD (Artificial Intelligence for Drug Discovery) technology employs deep learnings of human biology consisting of hundreds of millions of …See details»

NuMedii, Inc. Announces Pharmaceutical Discovery Collaboration …

Jan 20, 2020 Â· NuMedii's proprietary and dynamic AIDD (Artificial Intelligence for Drug Discovery) technology employs deep learnings of human biology consisting of hundreds of millions of …See details»

Media – NuMedii

NuMedii Announces Creation of World’s First Single-Cell Sequencing Atlas for Idiopathic Pulmonary Fibrosis by its Collaborators Press Release: Jan. 15, 2020 NuMedii, Inc. …See details»

NuMedii Announces New Indications Discovery Collaboration …

NuMedii, Inc., discovers effective new drugs by translating its predictive data intelligence technology into therapies with a higher probability of therapeutic success.See details»

linkstock.net © 2022. All rights reserved